Diagnosis and management of Guillain-Barré syndrome in ten steps
- PMID: 31541214
- PMCID: PMC6821638
- DOI: 10.1038/s41582-019-0250-9
Diagnosis and management of Guillain-Barré syndrome in ten steps
Abstract
Guillain-Barré syndrome (GBS) is a rare, but potentially fatal, immune-mediated disease of the peripheral nerves and nerve roots that is usually triggered by infections. The incidence of GBS can therefore increase during outbreaks of infectious diseases, as was seen during the Zika virus epidemics in 2013 in French Polynesia and 2015 in Latin America. Diagnosis and management of GBS can be complicated as its clinical presentation and disease course are heterogeneous, and no international clinical guidelines are currently available. To support clinicians, especially in the context of an outbreak, we have developed a globally applicable guideline for the diagnosis and management of GBS. The guideline is based on current literature and expert consensus, and has a ten-step structure to facilitate its use in clinical practice. We first provide an introduction to the diagnostic criteria, clinical variants and differential diagnoses of GBS. The ten steps then cover early recognition and diagnosis of GBS, admission to the intensive care unit, treatment indication and selection, monitoring and treatment of disease progression, prediction of clinical course and outcome, and management of complications and sequelae.
Conflict of interest statement
B.C.J. has received funding from Annexon Biosciences, Baxter, CSL Behring, Hansa Biopharma and Grifols. D.R.C. has received consultancy honoraria from Annexon Biosciences, argenx, Biotest Pharmaceuticals, Cigna Health Management, CSL Behring, DP Clinical, Grifols, Hansa Biopharma, New Enterprise Associates, Octapharma, Pharnext SAS, Polyneuron Pharmaceuticals, Seattle Genetics, Stealth BioTherapeutics, and Syntimmune. D.R.C is also on a data safety monitoring board for Pfizer, Sanofi, Alnylam Pharmaceuticals, PledPharma, and Momenta Pharma. Johns Hopkins University has licensed technology to AstraZeneca Pharmaceuticals, Genentech, Levicept, Seattle Genetics, Merrimack Pharmaceuticals, Levicept and Disarm Therapeutics, for which D.R.C. receives royalties. P.A.v.D. received a grant from Sanquin Blood supply for the SID-GBS randomized controlled trial, and a grant from Grifols to conduct the I-SID GBS study. R.A.C.H. has received consultancy honoraria from Laboratoire Francais du Fractionnement et des Biotechnologies (LFB S.A.). S.K. has received speaker honoraria from Teijin Pharma, Nihon Pharmaceutical and Japan Blood Products Organization, and research support from Nihon Pharmaceutical and Japan Blood Products Organization. R.R. is supported by a grant from CSL Behring. N.S. receives research support from Hovid Berhad. The other authors declare no competing interests.
Figures


References
-
- Asbury AK, Arnason BGW, Karp HR, McFarlin DE. Criteria for diagnosis of Guillain-Barré syndrome. Ann. Neurol. 1978;3:565–566. - PubMed
-
- Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 1990;27:S21–S24. - PubMed
-
- Sejvar JJ, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599–612. - PubMed
-
- Hadden RD, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann. Neurol. 1998;44:780–788. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical